Targeting triple negative breast cancer: Is p53 the answer?

Abstract Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15% of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2013-08, Vol.39 (5), p.541-550
Hauptverfasser:	Turner, Natalie, Moretti, Erica, Siclari, Olimpia, Migliaccio, Ilenia, Santarpia, Libero, D’Incalci, Maurizio, Piccolo, Stefano, Veronesi, Andrea, Zambelli, Alberto, Del Sal, Gianni, Di Leo, Angelo
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Breast Neoplasms - genetics Breast Neoplasms - metabolism Female Gynecology. Andrology. Obstetrics Hematology, Oncology and Palliative Medicine Humans Mammary gland diseases Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pharmacology. Drug treatments Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!